Additional sensitivity analyses yielded outcomes which were not materially different from the results of the primary analysis . . In subgroup analyses, there was a substantial interaction between treatment and BMI . The advantage of the levonorgestrel-IUS was greater in ladies with a BMI above 25 than in those with a BMI of 25 or less This finding appeared to be due to the superior outcome with usual medical treatment in leaner women . Improvements with the levonorgestrel-IUS were identical in both subgroups. None of the other exams for subgroup interaction were significant . General Standard of living and Sexual Activity SF-36 domains were generally improved from baseline in both groups at all time factors significantly, although the ratings for ladies in the levonorgestrel-IUS group were better than for all those in the usual-treatment group in seven of the eight domains in the analysis total time points ; mental health was the just domain for which there were no significant between-group distinctions.The rate of clinical benefit, which encompasses both objective responses and stable disease for at least 6 months, was selected because the primary end point for this scholarly study, rather than the more commonly used phase 2 efficacy end point of overall rate of response. The price of clinical advantage was selected based on the hypothesis that iniparib may exert cytostatic effects rather than, or furthermore to, cytotoxic effects when used in mixture with chemotherapy, leading to disease stabilization in addition to tumor regression.